Tag Archive for: Series A

Araris' linker technology enables site-specific payload attachment to a specific amino acid (Q295) within the IgG-Fc framework. When a payload is attached to this site, the antibody still maintains nearly identical performance (e.g. pharmacokinetics and effector functions) to the unconjugated, original antibody. Furthermore, the linker-payload is connected to the antibody through a very strong peptide bond resulting in exceptional stability in the blood stream and thus minimal adverse effects. © Araris Biotech AG
financing

Araris Biotech closes $24m Series A financing round

Swiss ADC maker Araris Biotech AG has added a $24m financing round to its CHF15.2m (S17.8m) seed round in 2020 to expand its portfolio of proprietary antibody drug conjugates.

Read more